308 related articles for article (PubMed ID: 8656777)
1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
de Clercq E
Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777
[No Abstract] [Full Text] [Related]
2. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
3. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
de Clercq E; Snoeck R
Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
[No Abstract] [Full Text] [Related]
4. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of HIV-1 drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors].
Nikolenko GN; Kotelkin AT; Oreshkova SF; Il'ichev AA
Mol Biol (Mosk); 2011; 45(1):108-26. PubMed ID: 21485502
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
Auwerx J; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring.
D'Aquila RT
Clin Lab Med; 1994 Jun; 14(2):393-422. PubMed ID: 7523021
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
Kilby JM; Saag MS
Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
[TBL] [Abstract][Full Text] [Related]
10. [Resistance to azidothymidine in human immunodeficiency virus (HIV) infection].
Karmanov EV; Lukashov VV
Mol Biol (Mosk); 1994; 28(1):7-20. PubMed ID: 7511784
[TBL] [Abstract][Full Text] [Related]
11. Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): a chemical survey from lead compounds to selected drugs for clinical trials.
Artico M
Farmaco; 1996 May; 51(5):305-31. PubMed ID: 8767842
[No Abstract] [Full Text] [Related]
12. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
13. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
[TBL] [Abstract][Full Text] [Related]
14. Structural mechanisms of HIV drug resistance.
Erickson JW; Burt SK
Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 reverse transcriptase inhibitors.
El Safadi Y; Vivet-Boudou V; Marquet R
Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus. Playing chess with reverse transcriptase.
Richman DD
Nature; 1993 Feb; 361(6413):588-9. PubMed ID: 7679776
[No Abstract] [Full Text] [Related]
17. [Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds].
Wainberg MA; Gu Z; Salomon H; Arts EJ; Kleiman L; Parniak MA; Morin N
C R Acad Sci III; 1995 Mar; 318(3):315-28. PubMed ID: 7540494
[TBL] [Abstract][Full Text] [Related]
18. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
19. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
20. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
Balzarini J
Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
